- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07560007
The Bleeding Assessment Tool (BAT) (BAT Protocol)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This study focuses on improving how doctors evaluate children who may have a mild bleeding disorder, such as von Willebrand disease or platelet function disorders. Doctors already use a standardized bleeding questionnaire to record a child's bleeding symptoms, but this can be difficult in younger children who often haven't had major bleeding challenges like surgery or dental work. To address this, the researchers added a small number of family history questions to the existing tool to see if knowing about bleeding problems in relatives helps predict whether a child truly has a bleeding disorder.
The study reviews several years of existing medical records from children and young adults seen in a pediatric hematology clinic. By comparing the standard questionnaire with the expanded version that includes family history, the researchers want to see which approach more accurately identifies patients who go on to receive a confirmed diagnosis. The goal is to help clinicians decide more confidently who needs further testing and who does not, reducing unnecessary and costly lab work while improving diagnosis, especially for children under 8 years old, where bleeding symptoms alone may be misleading.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- All individuals seen at CCHMC CBDI clinic for mild bleeding disorder with completed BAT+ at their new patient visit to Cincinnati Children's Hospital Medical Center (Base Campus or Liberty Campus) since 2019.
- If patient has multiple BAT+ scores will utilize the BAT+ score done at the new patient Hematology clinic CCHMC
Exclusion Criteria:
- Lack of BAT+ on new patient visit in outpatient setting to rule out mild
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
BAT CBDI patients
-All individuals seen at CCHMC CBDI clinic for mild bleeding disorder with completed BAT+ at their new patient visit to Cincinnati Children's Hospital Medical Center (Base Campus or Liberty Campus) since 2019.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
BAT+ Classification
Periodo de tiempo: From January 2019, through December 1, 2024
|
Dichotomous BAT classification (BAT+ vs BAT-) based on predefined age- and sex-specific BAT cutoffs.
|
From January 2019, through December 1, 2024
|
|
Bleeding Assessment Tool (BAT) Score
Periodo de tiempo: From January 2019, through December 1, 2024
|
Total BAT score calculated according to standardized criteria to quantify bleeding symptoms.
|
From January 2019, through December 1, 2024
|
|
Probability of Diagnosed Bleeding Disorder Based on BAT Score
Periodo de tiempo: From January 2019, through December 1, 2024
|
Predicted pretest probability of a confirmed bleeding disorder diagnosis (vWD, platelet function disorder, coagulation factor deficiency, or fibrinolytic disorder) estimated using logistic regression models with BAT score as a continuous predictor.
|
From January 2019, through December 1, 2024
|
|
Probability of Diagnosed Bleeding Disorder Based on BAT+ Status
Periodo de tiempo: From January 2019, through December 1, 2024
|
Predicted pretest probability of a confirmed bleeding disorder diagnosis estimated using logistic regression models with BAT+ classification as the primary predictor.
|
From January 2019, through December 1, 2024
|
|
Confirmed Bleeding Disorder Diagnosis by Category
Periodo de tiempo: From January 2019, through December 1, 2024
|
Final clinical diagnosis categorized as von Willebrand disease, platelet function disorder, coagulation factor deficiency, fibrinolytic disorder, or no bleeding disorder, using standardized diagnostic criteria.
|
From January 2019, through December 1, 2024
|
|
Diagnostic Accuracy of BAT
Periodo de tiempo: From January 2019, through December 1, 2024
|
Diagnostic accuracy of the Bleeding Assessment Tool (BAT) for identifying a confirmed bleeding disorder, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), using an initial cutoff score of ≥3.
Optimized cutoff scores will be reassessed using ROC analysis and Youden's Index.
|
From January 2019, through December 1, 2024
|
|
Diagnostic Accuracy of BAT+
Periodo de tiempo: From January 2019, through December 1, 2024
|
Diagnostic accuracy of the BAT+ classification for identifying a confirmed bleeding disorder, including sensitivity, specificity, PPV, and NPV, using an initial cutoff score of ≥6.
Optimized cutoffs will be reassessed using ROC analysis and Youden's Index.
|
From January 2019, through December 1, 2024
|
|
Likelihood Ratios for BAT
Periodo de tiempo: From January 2019, through December 1, 2024
|
Positive likelihood ratio for BAT at the initial cutoff score of ≥3 and at optimized cutoffs derived from ROC analysis.
|
From January 2019, through December 1, 2024
|
|
Likelihood Ratios for BAT+
Periodo de tiempo: From January 2019, through December 1, 2024
|
Positive likelihood ratio for BAT+ at the initial cutoff score of ≥6 and at optimized cutoffs derived from ROC analysis.
|
From January 2019, through December 1, 2024
|
|
Area Under the ROC Curve (AUC) for BAT
Periodo de tiempo: From January 2019, through December 1, 2024
|
Area under the receiver operating characteristic (ROC) curve for BAT scores derived from logistic regression models discriminating confirmed bleeding disorder diagnosis (yes/no).
|
From January 2019, through December 1, 2024
|
|
Area Under the ROC Curve (AUC) for BAT+
Periodo de tiempo: From January 2019, through December 1, 2024
|
Area under the ROC curve for BAT+ classification derived from logistic regression models discriminating confirmed bleeding disorder diagnosis (yes/no).
|
From January 2019, through December 1, 2024
|
|
Optimized BAT Cutoff Score
Periodo de tiempo: From January 2019, through December 1, 2024
|
Optimized BAT cutoff score identified using Youden's Index based on ROC curve analysis.
|
From January 2019, through December 1, 2024
|
|
Optimized BAT+ Cutoff Score
Periodo de tiempo: From January 2019, through December 1, 2024
|
Optimized BAT+ cutoff identified using Youden's Index based on ROC curve analysis.
|
From January 2019, through December 1, 2024
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010 Sep;8(9):2063-5. doi: 10.1111/j.1538-7836.2010.03975.x. No abstract available.
- Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999 Sep;82(3):1065-70.
- O'Brien SH. An update on pediatric bleeding disorders: bleeding scores, benign joint hypermobility, and platelet function testing in the evaluation of the child with bleeding symptoms. Am J Hematol. 2012 May;87 Suppl 1:S40-4. doi: 10.1002/ajh.23157. Epub 2012 Mar 28.
- Hayward CP. Diagnosis and management of mild bleeding disorders. Hematology Am Soc Hematol Educ Program. 2005:423-8. doi: 10.1182/asheducation-2005.1.423.
- Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995 Jul 10;155(13):1409-15.
- Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost. 2007 Jul;5 Suppl 1:157-66. doi: 10.1111/j.1538-7836.2007.02520.x.
- Bui J, Martyres D, James PD, Grabell J, Wu J, Steele M, Silva M, Rand ML, Blanchette VS, Barrowman N, Klaassen RJ. Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years. Pediatr Blood Cancer. 2019 Jun;66(6):e27709. doi: 10.1002/pbc.27709. Epub 2019 Mar 22.
- Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost. 2009 Aug;7(8):1418-21. doi: 10.1111/j.1538-7836.2009.03499.x. Epub 2009 May 30. No abstract available.
- Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012 Nov;10(11):2223-9. doi: 10.1111/j.1538-7836.2012.04923.x.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades Genéticas Congénitas
- Enfermedades hematológicas
- Trastornos de la coagulación de la sangre
- Trastornos hemorrágicos
- Trastornos de las plaquetas sanguíneas
- Trastornos de la coagulación de la sangre, hereditarios
- Trastornos de proteínas de coagulación
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades hemic y linfáticas
- Trastornos hemostáticos
- Enfermedades de von Willebrand
Otros números de identificación del estudio
- BAT Protocol: 2025-0160
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .